Kornimate/medical-research-clean huggingface dataset:
role of biomarkers to screen for obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: assess the relationship between obstructive sleep apnea and endocrine, inflammatory, and metabolic bio-markers in consecutively enrolled adult male patients with a clinical suspicion of obstructive sleep apnea.

obstructive sleep apnea (osa) is a disorder with high prevalence, estimated to occur in 34% of men and 17% of women , afflicting more than 100 million adults worldwide. osa is the third most common serious respiratory condition after asthma and copd. patients with untreated osa are at increased risk for hypertension, cardiovascular disease, heart failure, stroke, obesity, metabolic dysregulation, diabetes mellitus, daytime sleepiness, depression, accidents and are a significant burden on the healthcare system. unfortunately, up to 90% of individuals with osa remain without a diagnosis or therapy. the association between osa and adverse health consequences has led the american heart association and others to suggest that osa screening be integrated into routine clinical care. current tools for osa screening rely on questionnaires with low diagnostic accuracy from low-quality studies, as reported in meta-analyses, osa screening measures that are frequently used include the epworth sleepiness scale (ess) and stop-bang questionnaires. the ess assesses subjective daytime sleepiness but is nonspecific for osa, was not designed nor validated for osa screening. the recent american academy of sleep medicine (aasm) clinical practice guidelines report that more accurate and user-friendly screening tools, such as blood bio-markers, are needed to better predict osa diagnosis and severity, a recent review of potential osa bio-markers concludes that an optimal screening test should be clinically sensitive, specific, simple, timely, inexpensive, and correlate to disease severity. furthermore, bio-markers should make pathophysiological sense, reflecting functional changes that accompany osa. numerous individual osa blood bio-markers have been studied previously dysfunctions in metabolic and endocrine systems induced by osa, chronic inflammation, hypoxemia, sleep fragmentation, and stress are associated with alterations in bio-markers. these bio-markers include glycated hemoglobin (hba1c), c-reactive protein (crp), erythropoietin (epo), and uric acid,unfortunately, the diagnostic utility of individual bio-markers or combinations of markers is inconclusive in identifying osa.

Eligibility criteria:
inclusion criteria: * all patients with a clinical suspicion of obstructive sleep apnea enrolled to the investigator's chest department. exclusion criteria: * patients who previously treated as obstructive sleep apnea, or receiving opioid pain medications.
high dose inhaled nitric oxide for covid-19 (icu patients)

Conditions: COVID-19

Summary: novel therapies are desperately needed for treatment of covid-19 patients. at present, there are no proven interventions to prevent progression of the disease or to rapidly treat patients with covid-19 related respiratory failure. data on the original coronavirus -sars pneumonia suggested that high dose (\>160ppm) inhaled nitric oxide could have beneficial effects also on covid-19, due to the genomic similarities between these two coronaviruses (1-3). this study will test whether high dose inhaled nitric oxide is safe and can reverse virus burden and respiratory failure in patients on mechanical ventilation.


Eligibility criteria:
inclusion criteria: 1. confirmed infection with covid-19 positive rt-pcr tracheal aspirate prior to treatment 2. use of mechanical ventilation with or without ecmo 3. male or female ages \> 18 years 4. \< 14 days from symptom initiation to study enrolment and \< 7 days from intubation to study enrolment exclusion criteria: 1. patients on other interventional clinical trials 2. subjects diagnosed with congestive or unstable heart disease including heart failure, left ventricular dysfunction (lvef \< 40 %) or myocardial damage, severe pulmonary hypertension and/or unstable hypertension 3. subjects diagnosed with immunodeficiency 4. hematology: patients with clinically significant anemia e.g. hemoglobin \< 100 and thrombocytopenia e.g. platelets \< 75 5. subjects with clinically significant history of, or active bleeding including active pulmonary or gastrointestinal bleeding 6. hepatic function: patients with abnormal liver function defined as any two of the following alt \>3x uln, ast \>3x uln, total bilirubin \< 1.5 x uln 7. patient receiving drugs that have a contraindication with no e.g. use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as lidocaine, prilocaine, benzocaine or dapsone at screening as relevant to the proposed study population 8. pregnancy 9. subjects with a known hypersensitivity to methylene blue, subjects with glucose-6-phosphate dehydrogenase (g6pd) deficiency 10. known or suspected thalassemia, sickle cell disease, or other conditions associated with poor oxygen carrying capacity
automated fastener device versus manually tied knot in miavr

Conditions: Heart Valve Diseases

Summary: the aim of the investigator's study was to evaluate the efficacy and the safety of the cor-knot device in isolated aortic valve replacement (avr) by right anterior minithoracotomy (ramt). four hundred and forty patients were operated for avr by ramt. of these patients, 221 underwent isolated avr surgery with stented prosthesis. sutures were secured using the cor-knot titanium fastener in 63 patients and knots were hand-tied in 158. the aortic cross-clamping and cardiopulmonary bypass times were significantly decreased in the at group compared with the mt group. clinical outcomes were similar in the two groups, whether in the analysis of non-matched or matched groups. there was no difference in 30 day-mortality and the stroke and tia rates were comparable the automated cor-knot fastener is an easy-to-use, time-saving device which does not increase perioperative morbi-mortality in patients undergoing avr by right anterior minithoracotomy.


Eligibility criteria:
inclusion criteria: * age \> 18 years * elective patient * isolated aortic valve replacement with stented prosthesis * minimally-invasive approach (right anterior minithoracotomy) exclusion criteria: * associated procedure * aortic valve replacement with sutureless or rapid valve deployment prosthesis * active endocarditis * prior cardiac surgery
regular physical exercise and salt diet on coronary artery disease in patients with prehypertension(restrain pre-ht)

Conditions: Coronary Atherosclerosis; Cardiovascular Disease

Summary: the epidemic data shows that prehypertension is associated with cardiovascular disease, and heavy dietary salt intake could improve the developing of hypertension. we detected the risk factors of coronary atherosclerosis of prehypertensive patients with different levels of salt intake. the aim of this multicenter prospective, randomized controlled study is to evaluate regular physical exercise and salt diet effects on progression of coronary artery disease in patients with prehypertension.


Eligibility criteria:
inclusion criteria: aged 45-75 admission systolic bp between 120 and 139mmhg or diastolic bp between 80 and 89mmhg coronary artery stenosis was 30%-70% - exclusion criteria: with a history of myocardial infarction, coronary revascularization, congenital heart disease and cerebrovascular diseases -

Keywords: prehypertension coronary atherosclerosis cardiovascular disease
study of ingaron's effect on efficacy and resistance to antibiotics in community-acquired pneumonia

Conditions: Community-acquired Pneumonia

Summary: the primary purpose of this study is to effect of ingaron®, a lyophilisate for the preparation of a solution for intramuscular and subcutaneous administration of 100,000 iu (llc npp farmaklon, russia) on the effectiveness of antibiotic therapy in patients with community-acquired pneumonia who fell ill during the epidemiological rise of arvi.

pilot, open, single-centre, randomized controlled trial. patients will be prescribed basic combination antibiotic therapy. in addition to antibiotic therapy, half of the patients will receive ingaron®, a lyophilisate for the preparation of a solution for intramuscular and subcutaneous administration of 100,000 iu (llc npp farmaklon, russia). the study drug solution ingaron® will be administered intramuscularly at 100,000 iu once daily for 5 days.

Eligibility criteria:
inclusion criteria: 1. patients of the inpatient department of both sexes aged 18 to 60 years. 2. confirmed diagnosis - community-acquired pneumonia (causative agent not specified) of an uncomplicated typical course without respiratory failure and the duration of symptoms is not more than 14 days. 3. risk class of lethal outcome i-ii according to the fine scale. 4. availability of an informed consent voluntarily signed by the patient. exclusion criteria: 1. increased individual sensitivity to gamma interferon, ingaron® and / or excipients that are part of ingaron® or drugs used in antibacterial therapy. 2. the use of immunomodulating, immunostimulating or immunosuppressive therapy later than 1 month before enrollment in the study. 3. bronchial asthma and/or copd. 4. congestive heart failure. 5. acute diseases of the gastrointestinal tract or other pathologies that may affect the absorption, distribution, metabolism or excretion of drugs. 6. chronic liver and / or kidney disease or other pathologies that may affect the absorption, distribution, metabolism or excretion of drugs. 7. oncological diseases, autoimmune, immunosuppressive conditions at present or according to history. 8. cerebrovascular pathologies. 9. diabetes. 10. pregnancy or lactation. 11. smoking index over 10 pack/years. 12. data on severe nervous or mental diseases, including history. 13. violation of consciousness. 14. participation of the patient in other studies with the use of drugs or other methods of therapy, including clinical, currently or later than 1 month before inclusion in the study.

Keywords: interferon gamma ifn-g antibiotic resistance community-acquired pneumonia
rise versus advocacy-based enhanced care as usual for patients experiencing ipv

Conditions: Intimate Partner Violence (IPV)

Summary: this study aims to improve treatment for veterans health administration (vha) patients who experience intimate partner violence (ipv). this study will evaluate two brief counseling interventions for vha patients who have experienced ipv in the past 12 months: recovering from ipv through strength and empowerment (rise) and advocacy-based enhanced care as usual (ecau). the rise intervention includes up to 8 sessions and includes specific topic areas (e.g., social support, health effects, resources). the other intervention, ecau, includes a single session that includes supportive education about ipv and health effects, discussion of ways to increase safety, and information about resources. this study will test which approach is better for improving self-efficacy and other aspects of health. participants will answer surveys about their self-efficacy and other health and safety indicators (e.g., mental health symptoms) right before receiving treatment, approximately 12 weeks later, and then every three months after that for one year. participation in this research will last about 15 months.


Eligibility criteria:
inclusion criteria: * patients receiving care at an enrolled site/affiliated community-based outpatient clinic (cboc) * report experience of past-year physical, psychological, and/or sexual ipv on an established screening tool used to detect ipv in vha, and * be able to provide informed consent including permission to have intervention sessions recorded exclusion criteria: * severe cognitive impairment, * suicide or homicide intent with a specific plan * untreated or unstable symptoms of mania or psychosis

Keywords: rise enhanced care as usual (ecau) healthcare patients self-efficacy depression post-traumatic stress disorders (ptsd)
ending transmission of hiv, hcv, and stds and overdose in rural communities of people who inject drugs (ethic)

Conditions: HIV; Hepatitis C; Opioid-use Disorder; Injection Drug Use

Summary: this study will evaluate the referral to harm reduction services (hrs) including syringe services, naloxone overdose prevention, substance use treatment referral, hiv, hcv, and std testing and referral and linkage to care through capacity building of existing programs through client services data.

this is a prospective longitudinal type 1 hybrid implementation effectiveness study on the expansion of harm reduction services for people who inject drugs (pwid) and people who use opioids (pwuo) residing in high risk areas of rural southern illinois. this study record describes one component of the larger ending transmission of hiv, hcv, and stds and overdose in rural communities of people who inject drugs (ethic) study community response plan (crp) framework, specifically the expansion of harm reduction services intervention (hrs). the aim is to assess the effectiveness of expansion of evidenced based harm reduction services through our crp framework comprising: a) geographically targeted recruitment based on hot spot and vulnerability analyses, b) community engagement, c) recruitment via respondent driven sampling (rds), d) expanded surveillance for hiv and hcv, and e) concomitant hcv and opioid use treatment capacity expansion through the extension of community healthcare outcomes (echo) model. examination of facilitators and barriers impacting implementation of service delivery is evaluated through mixed methods process evaluation. the type 1 hybrid design is supported by conditions including the existing evidence based for benefits and minimal harm of "harm reduction services" and strong base for applicability of this intervention in the study setting (ie rural opioid use)

Eligibility criteria:
inclusion criteria: * 15 years of age and older * injected any drug in the past 30 days * used any opioids non-medically in the past 30 days * english speaking * able to provide informed consent at the time of the study visit exclusion criteria: * less than 15 years of age * not injected any drug in the past 30 days * not used any opioids non-medically in past 30 days * non-english speaking * has not injected any opioid drug to get high in the past 30 days * unable to provide informed consent at the time of the study visit

Keywords: hiv hepatitis c opioid-use disorder injection drug use harm reduction services
the effects of repeated exposure to antiseptics during covid-19 pandemic on skin parameters

Conditions: Irritation/Irritant; ICD - Irritant Contact Dermatitis; Antiseptic

Summary: the global coronavirus disease pandemic (covid-19) has led to an increased need to wear protective equipment such as wearing face masks and practicing hygiene measures such as more frequent use of antiseptics. these measures can lead to changes in the skin, the development of new inflammatory skin diseases or exacerbation of existing ones, with health professionals especially under the risk of developing these changes. changes in the skin of the hands due to the use of antiseptics have been observed in a number of studies, however, part of the study was based solely on subjects' self-assessment or clinical assessment of researchers, and only a small part on objective measurements of skin parameters. also, the impact of prolonged use of antiseptics and the impact of measures to prevent and protect against irritation such as topical application of emollient preparations have not been investigated. the impact of repeated use of antiseptics in the repeated exposure model on the forearms will be investigated. this model is a modification of the existing model of irritative dermatitis induced by sodium lauryl sulfate where the original irritant was replaced by an antiseptic solution.


Eligibility criteria:
inclusion criteria: * young, healthy volunteers who gave written informed consent exclusion criteria: * skin disease, skin damage on measurement sites * use of corticosteroids, antihistamines and immunomodulators a month prior the inclusion and during the trial * use of emollients three days prior the inclusion in the trial * non-adherence to the trial protocol * pregnancy and lactation * skin cancer * immunosuppression * exposure to artificial uv radiation
effect of exercise on prevention of weight gain

Conditions: Weight Loss

Summary: the purpose of this study is to examine the dose-response of exercise on prevention of weight gain in overweight adults.


Eligibility criteria:
inclusion criteria: 1. female or male 2. 18-55 years of age 3. bmi = 25-29.9 kg/m2 4. ability to provide informed consent. 5. ability to provide consent from their personal physician to participate in this study. exclusion criteria: 1. reporting regular exercise participation of at least 20 minutes per day on at least 3 days per week during the previous six months. (this study is designed to recruit relatively sedentary adults.) 2. diabetes, hypothyroidism, or other medical conditions which would affect energy metabolism. 3. women who are currently pregnant, pregnant within the previous six months, or planning on becoming pregnant within the next 12 months. (pregnancy during initial screening will be based on self-report and will be included on the detailed medical history that is completed by subjects. however, this will be confirmed with the urine pregnancy test that will be conducted prior to the baseline dexa.) 4. non-medicated resting systolic blood pressure \>160 mmhg or non-medicated resting diastolic blood pressure \>100 mmhg, or taking medication that would affect blood pressure. 5. taking medication that would affect resting heart rate or the heart rate response during exercise (e.g., beta blockade). 6. arrhythmia on resting or exercise electrocardiogram that would indicate that vigorous exercise was contraindicated. 7. history of myocardial infarction or valvular disease. 8. history of orthopedic complications that would prevent optimal participation in the exercise component (e.g., heel spurs, severe arthritis).
therapeutic mechanisms of epidural spinal cord stimulation

Conditions: Blood Pressure; Low Back Pain; Hypertension

Summary: the purpose of this study in patients undergoing routine care epidural spinal cord stimulation (scs) is to determine 1) whether scs reduces arterial blood pressure (bp) in patients which chronic low back pain and hypertension, 2) whether higher baseline bp (i.e., hypertension) predicts reductions in pain following scs, and finally 3) whether different scs waveforms elicits stimulus-evoked compound action potentials (ecaps) in spinal cord and at the cortex (electroencephalography, and magnetoenchphalography).

the purpose of this study in patients undergoing routine care epidural spinal cord stimulation (scs) is to determine 1) whether scs reduces arterial blood pressure (bp) in patients which chronic low back pain and hypertension, 2) whether higher baseline bp (i.e., hypertension) predicts reductions in pain following scs, and finally 3) whether different scs waveforms elicits stimulus-evoked compound action potentials (ecaps) in spinal cord and at the cortex (electroencephalography, and magnetoenchphalography). the investigators will identify patients with chronic pain who are scheduled for scs implant at the university of alabama at birmingham for management of chronic neuropathic pain as part of routine care. the research team will assess bp with an arm cuff arm cuff before and after the implant among patients providing written informed consent. the investigators' central clinical hypothesis is that scs decreases blood pressure in patients with chronic pain and comorbid hypertension. the investigators further hypothesize that the scs will improve serological markers of sympathetic nerve activity and kidney function, possibly due to reductions in spinal cord sympathetic nerve activity. a secondary hypothesis is that higher baseline blood pressure predicts larger reductions in blood pressure following scs implant. additionally, this project seeks to expand knowledge on therapeutic mechanisms of scs via recording electrophysiological responses at the spinal cord (via adjacent, unused scs contacts) and from eeg scalp recordings over the cerebral cortex.

Eligibility criteria:
inclusion criteria: 1. male or female, age 18-89 2. chronic pain for more than 3 months 3. willing to visit a research lab 4. willing to undergo a blood draw 5. able to provide written informed consent exclusion criteria 1. history of neurological disease (e.g., dementias, parkinson's) 2. history of stroke 3. current diagnosis of cancer 4. subject is unwilling or unable to comply with the protocol

Keywords: spinal cord stimulation epidural spinal cord stimulation scs arterial blood pressure
a study to evaluate the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage follicular lymphoma

Conditions: Lymphoma, Follicular

Summary: the purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage follicular lymphoma (fl).


Eligibility criteria:
inclusion criteria * participant has histologically confirmed grade 1, 2 or 3a follicular lymphoma (fl) or classic fl. formalin-fixed paraffin embedded (ffpe) archival tissue from 1 year prior to screening is allowed. if more than 1 year has passed, then a fresh biopsy must be obtained to confirm the diagnosis. * have no prior systemic treatment for follicular lymphoma. prior radiation therapy or surgery for previously diagnosed stage i disease is acceptable. * stage ii to iv disease. * deemed to need treatment by treating investigator. reasons for treatment can include, but are not limited to, the following:. i) bulky disease defined as:. a. a nodal or extra nodal (except spleen) mass \> 7cm in its greater diameter or, involvement of at least 3 nodal or extra nodal sites (each with a diameter greater than \>3 cm). ii) presence of at least one of the following b symptoms:. a. fever (\>38°c) of unclear etiology. b. night sweats. c. weight loss greater than 10% within the prior 6 months. iii) splenomegaly with inferior margin below the umbilical line. iv) any one of the following cytopenia due to lymphoma:. a. platelets \<100,000 cells/mm3 (100 x 109/l). b. absolute neutrophil count (anc) \< 1,000 cells/mm3 (1.0 x 109/l). c. hemoglobin \< 10g/dl (6.25 mmol/l). v) pleural or peritoneal serous effusion (irrespective of cell content). vi) any compressive syndrome (for example, but not restricted to ureteral, orbital, gastrointestinal). exclusion criteria * clinical evidence of transformed lymphoma by investigator assessment. * follicular large cell as per who 5th classification or grade 3b follicular lymphoma as per who 4th classification. * participant has any significant medical condition, active infection, laboratory abnormality, or psychiatric illness that would prevent the participation in the study. * other protocol-defined inclusion/exclusion criteria apply.

Keywords: follicular lymphoma grade 1-3a follicular lymphoma bms-986369 cc-99282 lymphoma golcadomide